Researchers led by Wang Yu at the Shenzhen Institutes of Advanced Technology of the Chinese Academy of Sciences reported dual small-molecule-controlled genome editing systems—PRINCE and Little Prince—that switch CRISPR activity on with drug inducers and keep it largely silent when the inducer is absent. The work was published in Science Translational Medicine.